Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 33Cyclophosphamide 23Filgrastim 18Peripheral Blood Stem Cell Transplantation 16Etoposide 13fludarabine phosphate 12Vincristine 12Prednisone 11Bortezomib 11sargramostim 10Radiotherapy 10Doxorubicin 8Cytarabine 8Cyclosporine 8Vorinostat 7Lenalidomide 7Cisplatin 7Biopsy 7tanespimycin 6Melphalan 6Magnetic Resonance Spectroscopy 6Ifosfamide 6bryostatin 1 5alvocidib 5aldesleukin 5Specimen Handling 5Methylprednisolone 5Methotrexate 5Interferon-alpha 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Follicular × oprelvekin × Clear all
NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡